丁香园 | 丁香通 | 人才 | 会议 | 药学 | 博客  
 点击次数:

走进诺和诺德 更多 >>

诺和诺德:让我们一起改变糖尿病

诺和诺德是一家致力于人类健康、以先进的生物技术造福患者、医生和社会的世界领先生物制药公司。

诺和诺德公司的历史最早可追溯至1923年,80多年来一直是世界糖尿病研究和药物开发领域的主导。诺和诺德总部位于丹麦首都哥本哈根,现在全球79个国家设有分支机构,6个国家设有生产厂,截至08年底,员工超过 27,000名,销售遍及180个国家。

诺和诺德凭借自身的研发实力成为世界糖尿病治疗领域先导,在行业内拥有最为广泛的糖尿病治疗产品,其中包括最先进的胰岛素给药系统产品。

 

土耳其Erciyes大学内分泌系顾问Fahrettin Kelestimur教授

转载请注明来自丁香园
发布日期:2009-12-22 18:26 文章来源:丁香园
分享到: 收藏夹 新浪微博 腾讯微博 开心网 豆瓣社区 人人网
关键词: 诺和锐 诺和诺德 novonordisk Fahrettin Kelestimur 糖尿病 胰岛素   点击次数:

 


Fahrettin Kelestimur
Kayseri, Turkey

Fahrettin Kelestimur is currently a consultant in the Department of Endocrinology at the School of Medicine of Erciyes University.

He was an Executive Committee member of the European Neuroendocrine Association (ENEA) and a member of the Executive Committee of European Society of Endocrinology (ESE). He is the former President of the Society of Endocrinology and Metabolism of Turkey (SEMT). He is also a member of various Study Groups.

Professor Kelestimur is a member of the Editorial Board of Growth Hormone and IGF Research and Expert Review in Endocrinology and Metabolism. He is the Associate Editor of Experimental and Clinical Endocrinology and Diabetes and a member of the
Advisory Board of the Journal of Endocrinological Investigation. His interests are neuroendocrinology, diabetes mellitus, reproductive endocrinology and pituitary medicine and is the author of over 152 peer-reviewed scientific articles.

编辑: xiaoyan 作者:丁香园通讯员

以下网友留言只代表网友个人观点,不代表网站观点